Takeda, Azurity Sue Glenmark to Block Copies of Edarbi Drug

Takeda Pharmaceutical Co. and Azurity Pharmaceuticals Inc. allege that a copy of Edarbi proposed by Glenmark Pharmaceuticals Ltd. infringes a patent for the high blood pressure treatment’s composition.

Glenmark’s copy—if approved by the US Food and Drug Administration before the patent’s March 2028 expiration “for use in accordance with its proposed labeling”—would infringe the patent, or would induce or contribute to its infringement by third parties, according to a complaint filed Dec. 16 in the US District Court for the District of Delaware.

Edarbi prevents the narrowing of blood vessels, reducing blood pressure and improving blood flow. Azurity is a unit ...